

Walter Berger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7187933/publications.pdf>

Version: 2024-02-01

333
papers

16,194
citations

17405

63
h-index

28224

105
g-index

342
all docs

342
docs citations

342
times ranked

22614
citing authors

#	ARTICLE	IF	CITATIONS
1	KP1019, A New Redox-Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients. <i>Chemistry and Biodiversity</i> , 2008, 5, 2140-2155.	1.0	732
2	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. <i>Cell</i> , 2016, 164, 1060-1072.	13.5	702
3	NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application. <i>Chemical Science</i> , 2014, 5, 2925-2932.	3.7	552
4	Anticancer Activity of Metal Complexes: Involvement of Redox Processes. <i>Antioxidants and Redox Signaling</i> , 2011, 15, 1085-1127.	2.5	420
5	Structure-activity relationships for ruthenium and osmium anticancer agents – towards clinical development. <i>Chemical Society Reviews</i> , 2018, 47, 909-928.	18.7	330
6	Green tea extract and (–)-epigallocatechin-3-gallate, the major tea catechin, exert oxidant but lack antioxidant activities. <i>FASEB Journal</i> , 2005, 19, 1-26.	0.2	264
7	Metal Drugs and the Anticancer Immune Response. <i>Chemical Reviews</i> , 2019, 119, 1519-1624.	23.0	237
8	Spatio-temporally precise activation of engineered receptor tyrosine kinases by light. <i>EMBO Journal</i> , 2014, 33, 1713-1726.	3.5	226
9	Resistance against novel anticancer metal compounds: Differences and similarities. <i>Drug Resistance Updates</i> , 2008, 11, 1-16.	6.5	201
10	Vaults and the major vault protein: Novel roles in signal pathway regulation and immunity. <i>Cellular and Molecular Life Sciences</i> , 2009, 66, 43-61.	2.4	196
11	Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2005, 131, 101-110.	1.2	186
12	Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. <i>Blood</i> , 2017, 129, 1831-1839.	0.6	164
13	Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339. <i>Journal of Biological Inorganic Chemistry</i> , 2010, 15, 737-748.	1.1	150
14	Impact of Metal Coordination on Cytotoxicity of 3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone (Triapine) and Novel Insights into Terminal Dimethylation. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 5032-5043.	2.9	143
15	Ophiobolin A induces paraptosis-like cell death in human glioblastoma cells by decreasing BKCa channel activity. <i>Cell Death and Disease</i> , 2013, 4, e561-e561.	2.7	140
16	Structure-Activity Relationship Analysis of Novel Derivatives of Narciclasine (an) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 147 Td (<i>Ama <i>Chemistry</i> , 2009, 52, 1100-1114.	2.9	133
17	Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications. <i>Journal of Cancer Research and Clinical Oncology</i> , 2005, 131, 355-363.	1.2	128
18	Organometallic anticancer complexes of lapachol: metal centre-dependent formation of reactive oxygen species and correlation with cytotoxicity. <i>Chemical Communications</i> , 2013, 49, 3348.	2.2	127

#	ARTICLE	IF	CITATIONS
19	Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action. <i>Chemical Science</i> , 2015, 6, 2449-2456.	3.7	127
20	Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum(III)]trithiocyanate (KP772; FFC24). <i>Biochemical Pharmacology</i> , 2006, 71, 426-440.	2.0	124
21	Mechanisms underlying reductant-induced reactive oxygen species formation by anticancer copper(II) compounds. <i>Journal of Biological Inorganic Chemistry</i> , 2012, 17, 409-423.	1.1	120
22	The sodium pump $\hat{\pm}1$ subunit: a disease progression-related target for metastatic melanoma treatment. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 3960-3972.	1.6	118
23	Enniatin Exerts p53-Dependent Cytostatic and p53-Independent Cytotoxic Activities against Human Cancer Cells. <i>Chemical Research in Toxicology</i> , 2007, 20, 465-473.	1.7	114
24	An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo. <i>Chemical Science</i> , 2017, 8, 2241-2250.	3.7	114
25	Down-Regulation of Sprouty2 in Non-Small Cell Lung Cancer Contributes to Tumor Malignancy via Extracellular Signal-Regulated Kinase Pathway-Dependent and -Independent Mechanisms. <i>Molecular Cancer Research</i> , 2007, 5, 509-520.	1.5	112
26	Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. <i>Hepatology</i> , 2011, 53, 854-864.	3.6	112
27	Targeting of eEF1A with <i>Amaryllidaceae</i> isocarboxtyrils as a strategy to combat melanomas. <i>FASEB Journal</i> , 2010, 24, 4575-4584.	0.2	110
28	Anticancer metal drugs and immunogenic cell death. <i>Journal of Inorganic Biochemistry</i> , 2016, 165, 71-79.	1.5	107
29	Expression of the major vault protein LRP in human non-small-cell lung cancer cells: Activation by short-term exposure to antineoplastic drugs. <i>International Journal of Cancer</i> , 2000, 88, 293-300.	2.3	105
30	Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis. <i>Neuro-Oncology</i> , 2015, 17, 1231-1240.	0.6	102
31	Review of cancer treatment with immune checkpoint inhibitors. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 85-91.	1.0	102
32	A SAR Study of Novel Antiproliferative Ruthenium and Osmium Complexes with Quinoxalinone Ligands in Human Cancer Cell Lines. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 3398-3413.	2.9	98
33	Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3408-3419.	1.9	97
34	An Organoruthenium Anticancer Agent Shows Unexpected Target Selectivity For Plectin. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 8267-8271.	7.2	97
35	Cellular Functions of Vaults and their Involvement in Multidrug Resistance. <i>Current Drug Targets</i> , 2006, 7, 923-934.	1.0	95
36	Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric Ependymoma. <i>Cancer Cell</i> , 2020, 38, 44-59.e9.	7.7	94

#	ARTICLE	IF	CITATIONS
37	Evidence for a role of FGF-2 and FGF receptors in the proliferation of non-small cell lung cancer cells. , 1999, 83, 415-423.		91
38	The activin axis in liver biology and disease. Mutation Research - Reviews in Mutation Research, 2006, 613, 123-137.	2.4	89
39	Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24). Biochemical Pharmacology, 2007, 73, 1873-1886.	2.0	88
40	FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities. Oncogene, 2008, 27, 4180-4190.	2.6	88
41	Narciclasine, a plant growth modulator, activates Rho and stress fibers in glioblastoma cells. Molecular Cancer Therapeutics, 2009, 8, 1739-1750.	1.9	88
42	<i>TERT</i> promoter mutations are associated with poor prognosis and cell immortalization in meningioma. Neuro-Oncology, 2018, 20, 1584-1593.	0.6	88
43	Anion-Exchange Chromatography Coupled to High-Resolution Mass Spectrometry: A Powerful Tool for Merging Targeted and Non-targeted Metabolomics. Analytical Chemistry, 2017, 89, 7667-7674.	3.2	87
44	Metal-Based Paullones as Putative CDK Inhibitors for Antitumor Chemotherapy. Journal of Medicinal Chemistry, 2007, 50, 6343-6355.	2.9	86
45	Expression and functional activity of the ABC-transporter proteins P-glycoprotein and multidrug-resistance protein 1 in human brain tumor cells and astrocytes. Journal of Neuro-Oncology, 2002, 57, 27-36.	1.4	85
46	Maleimide-functionalised platinum(IV) complexes as a synthetic platform for targeted drug delivery. Chemical Communications, 2013, 49, 2249.	2.2	84
47	Cell migration or cytokinesis and proliferation? â€“ Revisiting the â€œgo or growâ€ hypothesis in cancer cells in vitro. Experimental Cell Research, 2013, 319, 3094-3103.	1.2	84
48	Application of C₆₀ Fullerene-Doxorubicin Complex for Tumor Cell Treatment & In Vitro and In Vivo. Journal of Biomedical Nanotechnology, 2015, 11, 1139-1152.	0.5	83
49	Apelin promotes lymphangiogenesis and lymph node metastasis. Oncotarget, 2014, 5, 4426-4437.	0.8	81
50	Intrinsic and Acquired Forms of Resistance against the Anticancer Ruthenium Compound KP1019 [Indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A). Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 281-289.	1.3	80
51	Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. Biochemical and Biophysical Research Communications, 2009, 385, 454-459.	1.0	77
52	The major vault protein is responsive to and interferes with interferon-Î³-mediated STAT1 signals. Journal of Cell Science, 2006, 119, 459-469.	1.2	75
53	O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients. Neuro-Oncology, 2010, 12, 28-36.	0.6	75
54	The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo. European Journal of Cancer, 2013, 49, 3366-3375.	1.3	75

#	ARTICLE	IF	CITATIONS
55	Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2007, 103, 283-291.	1.1	74
56	Structure-Related Mode-of-Action Differences of Anticancer Organoruthenium Complexes with β -Diketonates. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 3984-3996.	2.9	74
57	FGF18 in colorectal tumour cells: autocrine and paracrine effects. <i>Carcinogenesis</i> , 2007, 29, 15-24.	1.3	73
58	Structural Simplification of Bioactive Natural Products with Multicomponent Synthesis. 3. Fused Uracil-Containing Heterocycles as Novel Topoisomerase-Targeting Agents. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 2012-2021.	2.9	73
59	Anticancer effects of zoledronic acid against human osteosarcoma cells. <i>Journal of Orthopaedic Research</i> , 2006, 24, 1145-1152.	1.2	72
60	Fibroblast Growth Factor Receptors as Therapeutic Targets in Human Melanoma: Synergism with BRAF Inhibition. <i>Journal of Investigative Dermatology</i> , 2011, 131, 2087-2095.	0.3	70
61	Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2015, 10, 738-746.	0.5	70
62	Mechanisms underlying the anticancer activities of the angucycline landomycin E. <i>Biochemical Pharmacology</i> , 2007, 74, 1713-1726.	2.0	69
63	Subtype-specific KRAS mutations in advanced lung adenocarcinoma: A retrospective study of patients treated with platinum-based chemotherapy. <i>European Journal of Cancer</i> , 2014, 50, 1819-1828.	1.3	68
64	Chromosomal imbalances in primary and metastatic melanomas. <i>Melanoma Research</i> , 2003, 13, 483-492.	0.6	67
65	Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration. <i>British Journal of Cancer</i> , 2010, 102, 1145-1156.	2.9	66
66	Water-soluble, biocompatible polyphosphazenes with controllable and pH-promoted degradation behavior. <i>Journal of Polymer Science Part A</i> , 2014, 52, 287-294.	2.5	65
67	Promyelocytic HL60 Cells Express NADPH Oxidase and Are Excellent Targets in a Rapid Spectrophotometric Microplate Assay for Extracellular Superoxide. <i>Toxicological Sciences</i> , 2003, 76, 376-383.	1.4	64
68	Deregulation of the activin/follistatin system in hepatocarcinogenesis. <i>Journal of Hepatology</i> , 2006, 45, 673-680.	1.8	64
69	Expression of the multidrug resistance-associated protein (MRP) and chemoresistance of human non-small-cell lung cancer cells. , 1997, 73, 84-93.		63
70	Galectin 1 Proangiogenic and Promigratory Effects in the Hs683 Oligodendroglioma Model Are Partly Mediated through the Control of BEX2 Expression. <i>Neoplasia</i> , 2009, 11, 485-496.	2.3	63
71	A Human Model of Epithelial to Mesenchymal Transition to Monitor Drug Efficacy in Hepatocellular Carcinoma Progression. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 850-860.	1.9	63
72	High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer. <i>Lung Cancer</i> , 2014, 83, 83-89.	0.9	63

#	ARTICLE	IF	CITATIONS
73	Overexpression of the human major vault protein in astrocytic brain tumor cells. <i>International Journal of Cancer</i> , 2001, 94, 377-382.	2.3	62
74	Oxidative stress and DNA interactions are not involved in Enniatin and Beauvericin mediated apoptosis induction. <i>Molecular Nutrition and Food Research</i> , 2009, 53, 1112-1122.	1.5	61
75	Dual inhibition of EGFR and mTOR pathways in small cell lung cancer. <i>British Journal of Cancer</i> , 2010, 103, 622-628.	2.9	61
76	C60 fullerene enhances cisplatin anticancer activity and overcomes tumor cell drug resistance. <i>Nano Research</i> , 2017, 10, 652-671.	5.8	61
77	Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age. <i>Neuro-Oncology</i> , 2013, 15, 423-432.	0.6	60
78	Comparative studies of oxaliplatin-based platinum ($Pt(IV)$) complexes in different in vitro and in vivo tumor models. <i>Metallomics</i> , 2017, 9, 309-322.	1.0	60
79	Fibroblast Growth Factor Receptor Inhibition Is Active against Mesothelioma and Synergizes with Radio- and Chemotherapy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 763-772.	2.5	59
80	Quantitative bioimaging by LA-ICP-MS: a methodological study on the distribution of Pt and Ru in viscera originating from cisplatin- and KP1339-treated mice. <i>Metallomics</i> , 2014, 6, 1616-1625.	1.0	58
81	Trabectedin has promising antineoplastic activity in high grade meningioma. <i>Cancer</i> , 2012, 118, 5038-5049.	2.0	57
82	Metal-Arene Complexes with Indolo[3,2-c]-quinolines: Effects of Ruthenium vs Osmium and Modifications of the Lactam Unit on Intermolecular Interactions, Anticancer Activity, Cell Cycle, and Cellular Accumulation. <i>Organometallics</i> , 2013, 32, 903-914.	1.1	57
83	Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma. <i>British Journal of Cancer</i> , 2014, 110, 984-990.	2.9	57
84	EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 134.	3.5	57
85	Possible role of the multidrug resistance-associated protein (MRP) in chemoresistance of human melanoma cells. <i>International Journal of Cancer</i> , 1997, 71, 108-115.	2.3	56
86	The gallium complex KP46 exerts strong activity against primary explanted melanoma cells and induces apoptosis in melanoma cell lines. <i>Melanoma Research</i> , 2009, 19, 283-293.	0.6	56
87	Activins and activin antagonists in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2008, 14, 1699.	1.4	56
88	Interactions between ABC transport proteins and the secondary Fusarium metabolites enniatin and beauvericin. <i>Molecular Nutrition and Food Research</i> , 2009, 53, 904-920.	1.5	55
89	Beauvericin and enniatin: emerging toxins and/or remedies?. <i>World Mycotoxin Journal</i> , 2010, 3, 415-430.	0.8	55
90	Galectin-1 Is Implicated in the Protein Kinase C μ /Vimentin-Controlled Trafficking of Integrin β 1 in Glioblastoma Cells. <i>Brain Pathology</i> , 2010, 20, 39-49.	2.1	55

#	ARTICLE	IF	CITATIONS
91	Targeted Proteolysis of Plectin Isoform 1a Accounts for Hemidesmosome Dysfunction in Mice Mimicking the Dominant Skin Blistering Disease EBS-Ogna. <i>PLoS Genetics</i> , 2011, 7, e1002396.	1.5	55
92	Tumor-Targeting of EGFR Inhibitors by Hypoxia-Mediated Activation. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 12930-12935.	7.2	55
93	Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation. <i>Oncotarget</i> , 2012, 3, 399-413.	0.8	55
94	Hydrogen peroxide mediates EGCG-induced antioxidant protection in human keratinocytes. <i>Free Radical Biology and Medicine</i> , 2010, 49, 1444-1452.	1.3	54
95	Anticancer Activity of Methyl-Substituted Oxaliplatin Analogs. <i>Molecular Pharmacology</i> , 2012, 81, 719-728.	1.0	54
96	Intrinsic MDR-1 gene and P-glycoprotein expression in human melanoma cell lines. <i>International Journal of Cancer</i> , 1994, 59, 717-723.	2.3	53
97	Multiple chromosomal abnormalities in human liver (pre)neoplasia. <i>Journal of Hepatology</i> , 2004, 40, 660-668.	1.8	53
98	DNA Damage, Somatic Aneuploidy, and Malignant Sarcoma Susceptibility in Muscular Dystrophies. <i>PLoS Genetics</i> , 2011, 7, e1002042.	1.5	53
99	Seven Novel and Stable Translocations Associated with Oncogenic Gene Expression in Malignant Melanoma. <i>Neoplasia</i> , 2005, 7, 303-311.	2.3	52
100	The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 387-400.	1.1	52
101	Organometallic indolo[3,2-c]quinolines versus indolo[3,2-d]benzazepines: synthesis, structural and spectroscopic characterization, and biological efficacy. <i>Journal of Biological Inorganic Chemistry</i> , 2010, 15, 903-918.	1.1	51
102	{(1 <i>R</i> ,2 <i>R</i> ,4 <i>R</i>)-4-Methyl-1,2-cyclohexanediamine}oxalatoplatinum(II): A Novel Enantiomerically Pure Oxaliplatin Derivative Showing Improved Anticancer Activity in Vivo. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 7356-7364.	2.9	51
103	Mouse tissue distribution and persistence of the food-born fusariotoxins Enniatin B and Beauvericin. <i>Toxicology Letters</i> , 2016, 247, 35-44.	0.4	51
104	High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 13388-13399.	0.8	50
105	X-ray Absorption Near Edge Structure Spectroscopy to Resolve the in Vivo Chemistry of the Redox-Active Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019). <i>Journal of Medicinal Chemistry</i> , 2013, 56, 1182-1196.	2.9	49
106	A Novel Class of Bis- and Tris-Chelate Diam(m)inebis(dicarboxylato)platinum(IV) Complexes as Potential Anticancer Prodrugs. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 6751-6764.	2.9	49
107	Another step toward DNA selective targeting: Ni ^{II} and Cu ^{II} complexes of a Schiff base ligand able to bind gene promoter G-quadruplexes. <i>Dalton Transactions</i> , 2016, 45, 7758-7767.	1.6	49
108	Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2011, 15, 829-846.	1.5	48

#	ARTICLE	IF	CITATIONS
109	Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?. <i>Current Pharmaceutical Design</i> , 2014, 20, 2881-2898.	0.9	48
110	Comparative in vitro and in vivo pharmacological investigation of platinum(IV) complexes as novel anticancer drug candidates for oral application. <i>Journal of Biological Inorganic Chemistry</i> , 2015, 20, 89-99.	1.1	47
111	Peroxisome proliferators do not increase DNA synthesis in purified rat hepatocytes. <i>Carcinogenesis</i> , 2001, 22, 519-523.	1.3	46
112	Synergistic Anticancer Activity of Arsenic Trioxide with Erlotinib Is Based on Inhibition of EGFR-Mediated DNA Double-Strand Break Repair. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1073-1084.	1.9	46
113	Major vault protein supports glioblastoma survival and migration by upregulating the EGFR/PI3K signalling axis. <i>Oncotarget</i> , 2013, 4, 1904-1918.	0.8	46
114	Temsirolimus Inhibits Malignant Pleural Mesothelioma Growth In Vitro and In Vivo: Synergism with Chemotherapy. <i>Journal of Thoracic Oncology</i> , 2011, 6, 852-863.	0.5	45
115	The metastatic microenvironment: Claudin-1 suppresses the malignant phenotype of melanoma brain metastasis. <i>International Journal of Cancer</i> , 2015, 136, 1296-1307.	2.3	44
116	Sensitivity towards the GRP78 inhibitor KP1339/IT-139 is characterized by apoptosis induction via caspase 8 upon disruption of ER homeostasis. <i>Cancer Letters</i> , 2017, 404, 79-88.	3.2	44
117	Differential Effects of Polymorphic Alleles of <i>FGF Receptor 4</i> on Colon Cancer Growth and Metastasis. <i>Cancer Research</i> , 2012, 72, 5767-5777.	0.4	43
118	MP AzeFlu is more effective than fluticasone propionate for the treatment of allergic rhinitis in children. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 1219-1222.	2.7	43
119	Self-assembled Pt ₂ L ₂ boxes strongly bind G-quadruplex DNA and influence gene expression in cancer cells. <i>Dalton Transactions</i> , 2017, 46, 329-332.	1.6	43
120	Pretreatment Serum C-Reactive Protein Levels Predict Benefit From Multimodality Treatment Including Radical Surgery in Malignant Pleural Mesothelioma. <i>Annals of Surgery</i> , 2012, 256, 357-362.	2.1	42
121	Tumor microenvironment in focus: LA-ICP-MS bioimaging of a preclinical tumor model upon treatment with platinum(IV)-based anticancer agents. <i>Metallomics</i> , 2015, 7, 1256-1264.	1.0	42
122	Impact of Stepwise NH ₂ -Methylation of Triapine on the Physicochemical Properties, Anticancer Activity, and Resistance Circumvention. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 6739-6752.	2.9	42
123	New cellular tools reveal complex epithelial-mesenchymal interactions in hepatocarcinogenesis. <i>British Journal of Cancer</i> , 2008, 99, 151-159.	2.9	40
124	Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018, 13, 258-272.	0.5	40
125	The Na ⁺ /K ⁺ -ATPase is the Achilles Heel of multi-drug-resistant cancer cells. <i>Cancer Letters</i> , 2009, 282, 30-34.	3.2	39
126	Lung cancer in never smokers. <i>Future Oncology</i> , 2011, 7, 1195-1211.	1.1	39

#	ARTICLE	IF	CITATIONS
127	Hellebrin and its aglycone form hellebrigenin display similar in vitro growth inhibitory effects in cancer cells and binding profiles to the alpha subunits of the Na ⁺ /K ⁺ -ATPase. <i>Molecular Cancer</i> , 2013, 12, 33.	7.9	39
128	Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study. <i>British Journal of Cancer</i> , 2015, 112, 783-792.	2.9	39
129	Behavior of platinum(^{iv}) complexes in models of tumor hypoxia: cytotoxicity, compound distribution and accumulation. <i>Metallomics</i> , 2016, 8, 422-433.	1.0	39
130	Subcellular Duplex DNA and Gâ€Quadruplex Interaction Profiling of a Hexagonal Pt ^{II} Metallacycle. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 8007-8012.	7.2	39
131	Interaction with Ribosomal Proteins Accompanies Stress Induction of the Anticancer Metallodrug BOLDâ€100/KP1339 in the Endoplasmic Reticulum. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 5063-5068.	7.2	39
132	Osmium(IV) complexes with 1H- and 2H-indazoles: Tautomer identity versus spectroscopic properties and antiproliferative activity. <i>Journal of Inorganic Biochemistry</i> , 2012, 113, 47-54.	1.5	38
133	Sphaeropsidin A shows promising activity against drug-resistant cancer cells by targeting regulatory volume increase. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 3731-3746.	2.4	38
134	The thiosemicarbazone Me ₂ NNMe ₂ induces paraptosis by disrupting the ER thiol redox homeostasis based on protein disulfide isomerase inhibition. <i>Cell Death and Disease</i> , 2018, 9, 1052.	2.7	38
135	Expression of the major vault protein LRP in human non-small-cell lung cancer cells: activation by short-term exposure to antineoplastic drugs. <i>International Journal of Cancer</i> , 2000, 88, 293-300.	2.3	38
136	Nanoformulation Improves Activity of the (pre)Clinical Anticancer Ruthenium Complex KP1019. <i>Journal of Biomedical Nanotechnology</i> , 2014, 10, 877-884.	0.5	36
137	Multi-scale imaging of anticancer platinum(^{iv}) compounds in murine tumor and kidney. <i>Chemical Science</i> , 2016, 7, 3052-3061.	3.7	36
138	Destruixins: Fungal-derived cyclohexadepsipeptides with multifaceted anticancer and antiangiogenic activities. <i>Biochemical Pharmacology</i> , 2013, 86, 361-377.	2.0	35
139	Fibroblast growth factor receptor 4: a putative key driver for the aggressive phenotype of hepatocellular carcinoma. <i>Carcinogenesis</i> , 2014, 35, 2331-2338.	1.3	35
140	Triapine and a More Potent Dimethyl Derivative Induce Endoplasmic Reticulum Stress in Cancer Cells. <i>Molecular Pharmacology</i> , 2014, 85, 451-459.	1.0	35
141	Poly(lactic acid) nanoparticles of the lead anticancer ruthenium compound KP1019 and its surfactant-mediated activation. <i>Dalton Transactions</i> , 2014, 43, 1096-1104.	1.6	35
142	Active vitamin D potentiates the anti-neoplastic effects of calcium in the colon: A cross talk through the calcium-sensing receptor. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016, 155, 231-238.	1.2	35
143	Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis. <i>Oncolmmunology</i> , 2018, 7, e1424676.	2.1	35
144	Overexpression of Hsp27 affects the metastatic phenotype of human melanoma cells in vitro. <i>Cell Stress and Chaperones</i> , 2002, 7, 177.	1.2	35

#	ARTICLE	IF	CITATIONS
145	Screening of anti-glioma effects induced by sigma-1 receptor ligands: Potential new use for old anti-psychiatric medicines. <i>European Journal of Cancer</i> , 2009, 45, 2893-2905.	1.3	34
146	Unsymmetric Mono- and Dinuclear Platinum(IV) Complexes Featuring an Ethylene Glycol Moiety: Synthesis, Characterization, and Biological Activity. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 11052-11061.	2.9	34
147	Structure-Activity Relationships of Triple-Action Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating Ligands. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 12132-12151.	2.9	34
148	Activins and follistatins: Emerging roles in liver physiology and cancer. <i>World Journal of Hepatology</i> , 2009, 1, 17.	0.8	34
149	In vitro studies on cisplatin focusing on kinetic aspects of intracellular chemistry by LC-ICP-MS. <i>Metallomics</i> , 2013, 5, 636.	1.0	33
150	Ophiobolin A, a sesterterpenoid fungal phytotoxin, displays higher in vitro growth-inhibitory effects in mammalian than in plant cells and displays in vivo antitumor activity. <i>International Journal of Oncology</i> , 2013, 43, 575-585.	1.4	33
151	Fibroblast growth factor receptor 3 isoforms: Novel therapeutic targets for hepatocellular carcinoma?. <i>Hepatology</i> , 2015, 62, 1767-1778.	3.6	33
152	Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 122.	3.5	33
153	Cancer Cell Resistance Against the Clinically Investigated Thiosemicarbazone COTI-2 Is Based on Formation of Intracellular Copper Complex Glutathione Adducts and ABCC1-Mediated Efflux. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 13719-13732.	2.9	33
154	Dynamics of chemosensitivity and chromosomal instability in recurrent glioblastoma. <i>British Journal of Cancer</i> , 2007, 96, 960-969.	2.9	32
155	Up-regulation of 12(S)-lipoxygenase induces a migratory phenotype in colorectal cancer cells. <i>Experimental Cell Research</i> , 2012, 318, 768-778.	1.2	32
156	Novel p53-dependent anticancer strategy by targeting iron signaling and BNIP3L-induced mitophagy. <i>Oncotarget</i> , 2016, 7, 1242-1261.	0.8	32
157	Synthesis and in vivo anticancer evaluation of poly(organo)phosphazene-based metallodrug conjugates. <i>Dalton Transactions</i> , 2017, 46, 12114-12124.	1.6	32
158	FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal. <i>Carcinogenesis</i> , 2018, 39, 534-545.	1.3	32
159	Synthesis and biological evaluation of biotin-conjugated anticancer thiosemicarbazones and their iron(III) and copper(II) complexes. <i>Journal of Inorganic Biochemistry</i> , 2019, 190, 85-97.	1.5	32
160	Temozolomide-induced modification of the CXC chemokine network in experimental gliomas. <i>International Journal of Oncology</i> , 2011, 38, 1453-64.	1.4	31
161	Promoter methylation patterns of <i>ABCB1</i> , <i>ABCC1</i> and <i>ABCG2</i> in human cancer cell lines, multidrug-resistant cell models and tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients. <i>Oncotarget</i> , 2016, 7, 73347-73369.	0.8	31
162	Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain. <i>Neuro-Oncology</i> , 2017, 19, 1183-1194.	0.6	31

#	ARTICLE	IF	CITATIONS
163	A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance. <i>Communications Chemistry</i> , 2022, 5, .	2.0	31
164	Impact of CYP24A1 overexpression on growth of colorectal tumour xenografts in mice fed with vitamin D and soy. <i>International Journal of Cancer</i> , 2016, 138, 440-450.	2.3	29
165	Effect of 1,25-dihydroxyvitamin D3 on the Wnt pathway in non-malignant colonic cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016, 155, 224-230.	1.2	29
166	The plasma membrane Ca ²⁺ pump PMCA4b inhibits the migratory and metastatic activity of BRAF mutant melanoma cells. <i>International Journal of Cancer</i> , 2017, 140, 2758-2770.	2.3	29
167	Bioimaging of isosteric osmium and ruthenium anticancer agents by LA-ICP-MS. <i>Metallomics</i> , 2018, 10, 388-396.	1.0	29
168	The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma. <i>Journal of Molecular Medicine</i> , 2019, 97, 231-242.	1.7	29
169	Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1547-1556.	1.9	28
170	Novel Inhibitors of Cyclin-Dependent Kinases Combat Hepatocellular Carcinoma without Inducing Chemoresistance. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1947-1957.	1.9	28
171	Epigenetic downregulation of integrin $\alpha 7$ increases migratory potential and confers poor prognosis in malignant pleural mesothelioma. <i>Journal of Pathology</i> , 2015, 237, 203-214.	2.1	28
172	The naturally born fusariotoxin enniatin B and sorafenib exert synergistic activity against cervical cancer in vitro and in vivo. <i>Biochemical Pharmacology</i> , 2015, 93, 318-331.	2.0	28
173	Distinct activity of the bone-targeted gallium compound KP46 against osteosarcoma cells - synergism with autophagy inhibition. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 52.	3.5	28
174	Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients. <i>Acta Neuropathologica Communications</i> , 2020, 8, 78.	2.4	28
175	Glycoprotein regulates chemosensitivity in early developmental stages of the mouse. <i>FASEB Journal</i> , 1993, 7, 1499-1506.	0.2	27
176	Vemurafenib Resistance Signature by Proteome Analysis Offers New Strategies and Rational Therapeutic Concepts. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 757-768.	1.9	27
177	Ecdysteroids Sensitize MDR and Non-MDR Cancer Cell Lines to Doxorubicin, Paclitaxel, and Vincristine but Tend to Protect Them from Cisplatin. <i>BioMed Research International</i> , 2015, 2015, 1-8.	0.9	27
178	Macromolecular Pt(IV) Prodrugs from Poly(organo)phosphazenes. <i>Macromolecular Bioscience</i> , 2016, 16, 1239-1249.	2.1	27
179	{Ru(CO) _x }-Core complexes with benzimidazole ligands: synthesis, X-ray structure and evaluation of anticancer activity in vivo. <i>Dalton Transactions</i> , 2017, 46, 3025-3040.	1.6	27
180	Rapid generation of hydrogen peroxide contributes to the complex cell death induction by the angucycline antibiotic landomycin E. <i>Free Radical Biology and Medicine</i> , 2017, 106, 134-147.	1.3	27

#	ARTICLE	IF	CITATIONS
181	Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer. <i>Oncotarget</i> , 2016, 7, 69976-69990.	0.8	27
182	TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAFV600E/TERT promoter double-mutated glioma. <i>Acta Neuropathologica Communications</i> , 2019, 7, 128.	2.4	26
183	Gliomasphere marker combinatorics: multidimensional flow cytometry detects <sc>CD</sc>44+/<sc>CD</sc>133+/<sc>ITGA</sc>6+/<sc>CD</sc>36+ signature. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 281-292.	1.6	26
184	Synergistic Effects of Erlotinib and Everolimus on Bronchial Carcinoids and Large-Cell Neuroendocrine Carcinomas with Activated EGFR/AKT/mTOR Pathway. <i>Neuroendocrinology</i> , 2012, 96, 228-237.	1.2	25
185	Calpain-Mediated Integrin Deregulation as a Novel Mode of Action for the Anticancer Gallium Compound KP46. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2436-2449.	1.9	25
186	Silencing of protein kinase D2 induces glioma cell senescence via p53-dependent and -independent pathways. <i>Neuro-Oncology</i> , 2014, 16, 933-945.	0.6	25
187	EV1 promotes tumor growth via transcriptional repression of MS4A3. <i>Journal of Hematology and Oncology</i> , 2015, 8, 28.	6.9	25
188	Electronic State of Sodium trans-[Tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339) in Tumor, Liver and Kidney Tissue of a SW480-bearing Mouse. <i>Scientific Reports</i> , 2017, 7, 40966.	1.6	25
189	FGF5 is expressed in melanoma and enhances malignancy <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2017, 8, 87750-87762.	0.8	25
190	SP-transcription factors are involved in basal MVP promoter activity and its stimulation by HDAC inhibitors. <i>Biochemical and Biophysical Research Communications</i> , 2004, 317, 235-243.	1.0	24
191	Telomerase- and Alternative Telomere Lengthening-Independent Telomere Stabilization in a Metastasis-Derived Human Non-Small Cell Lung Cancer Cell Line: Effect of Ectopic hTERT. <i>Cancer Research</i> , 2006, 66, 3584-3592.	0.4	24
192	Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells. <i>British Journal of Cancer</i> , 2012, 107, 1978-1986.	2.9	24
193	The major vault protein mediates resistance to epidermal growth factor receptor inhibition in human hepatoma cells. <i>Cancer Letters</i> , 2012, 319, 164-172.	3.2	24
194	Functional Classification of Cellular Proteome Profiles Support the Identification of Drug Resistance Signatures in Melanoma Cells. <i>Journal of Proteome Research</i> , 2013, 12, 3264-3276.	1.8	24
195	Triapine-mediated ABCB1 induction via PKC induces widespread therapy unresponsiveness but is not underlying acquired triapine resistance. <i>Cancer Letters</i> , 2015, 361, 112-120.	3.2	24
196	Myeloid STAT3 promotes formation of colitis-associated colorectal cancer in mice. <i>Oncolmmunology</i> , 2015, 4, e998529.	2.1	24
197	Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth <i>In Vivo</i> . <i>Clinical Cancer Research</i> , 2018, 24, 3729-3740.	3.2	24
198	Biological activity of PtIV prodrugs triggered by riboflavin-mediated bioorthogonal photocatalysis. <i>Scientific Reports</i> , 2018, 8, 17198.	1.6	24

#	ARTICLE	IF	CITATIONS
199	Albumin-targeting of an oxaliplatin-releasing platinum(<i>iv</i>) prodrug results in pronounced anticancer activity due to endocytotic drug uptake <i>in vivo</i> . <i>Chemical Science</i> , 2021, 12, 12587-12599.	3.7	24
200	Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019. <i>Journal of Biological Inorganic Chemistry</i> , 2011, 16, 1205-1215.	1.1	23
201	Specific antioxidant compounds differentially modulate cytotoxic activity of doxorubicin and cisplatin: <i>in vitro</i> and <i>in vivo</i> study. <i>Croatian Medical Journal</i> , 2014, 55, 206-217.	0.2	23
202	EGFR-targeting peptide-coupled platinum(IV) complexes. <i>Journal of Biological Inorganic Chemistry</i> , 2017, 22, 591-603.	1.1	23
203	Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup. <i>Clinical Cancer Research</i> , 2020, 26, 3819-3830.	3.2	23
204	Discovery and Characterization of <i>R</i> - <i>S</i> - <i>N</i> -3-Cyanophenyl- <i>N</i> -(6- <i>tert</i> -butoxycarbonylamino-3,4-dihydro-2,2-dimethyl-2 <i>H</i> -1-benzop a New Histone Deacetylase Class III Inhibitor Exerting Antiproliferative Activity against Cancer Cell Lines. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 4714-4733.	2.9	22
205	The Natural Fungal Metabolite Beauvericin Exerts Anticancer Activity <i>In Vivo</i> : A Pre-Clinical Pilot Study. <i>Toxins</i> , 2017, 9, 258.	1.5	22
206	Serum-binding properties of isosteric ruthenium and osmium anticancer agents elucidated by SEC-ICP-MS. <i>Monatshefte für Chemie</i> , 2018, 149, 1719-1726.	0.9	22
207	Nanoformulations of anticancer FGFR inhibitors with improved therapeutic index. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 2632-2643.	1.7	22
208	Ribonucleotide Reductase as One Important Target of [Tris(1,10-phenanthroline)lanthanum(III)] Trithiocyanate (KP772). <i>Current Cancer Drug Targets</i> , 2009, 9, 595-607.	0.8	21
209	Quantitative determination of intact free cisplatin in cell models by LC-ICP-MS. <i>Journal of Analytical Atomic Spectrometry</i> , 2011, 26, 109-115.	1.6	21
210	MET expression in melanoma correlates with a lymphangiogenic phenotype. <i>Human Molecular Genetics</i> , 2012, 21, 3387-3396.	1.4	21
211	Enhanced Anticancer Activity and Circumvention of Resistance Mechanisms by Novel Polymeric/Phospholipidic Nanocarriers of Doxorubicin. <i>Journal of Biomedical Nanotechnology</i> , 2014, 10, 1369-1381.	0.5	21
212	Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma – A multi-institutional study. <i>European Journal of Cancer</i> , 2016, 63, 64-73.	1.3	21
213	Preclinical studies on metal based anticancer drugs as enabled by integrated metallomics and metabolomics. <i>Metallomics</i> , 2019, 11, 1716-1728.	1.0	21
214	Whole genome amplification for CGH analysis: Linker-adapter PCR as the method of choice for difficult and limited samples. <i>Cytometry</i> , 2004, 61A, 26-34.	1.8	20
215	EV11 Inhibits Apoptosis Induced by Antileukemic Drugs via Upregulation of CDKN1A/p21/WAF in Human Myeloid Cells. <i>PLoS ONE</i> , 2013, 8, e56308.	1.1	20
216	Differences in protein binding and excretion of Triapine and its Fe(III) complex. <i>Journal of Inorganic Biochemistry</i> , 2016, 160, 61-69.	1.5	20

#	ARTICLE	IF	CITATIONS
217	Ruthenium ^{II} -arene complexes bearing naphthyl-substituted 1,3-dioxindan-2-carboxamides ligands for G-quadruplex DNA recognition. <i>Dalton Transactions</i> , 2019, 48, 12040-12049.	1.6	20
218	New 5-Aryl-1H-imidazoles Display in Vitro Antitumor Activity against Apoptosis-Resistant Cancer Models, Including Melanomas, through Mitochondrial Targeting. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 6626-6637.	2.9	19
219	Prenylation Inhibition-Induced Cell Death in Melanoma: Reduced Sensitivity in BRAF Mutant/PTEN Wild-Type Melanoma Cells. <i>PLoS ONE</i> , 2015, 10, e0117021.	1.1	19
220	Combined proteomics/miRNomics of dendritic cell immunotherapy-treated glioblastoma patients as a screening for survival-associated factors. <i>Npj Vaccines</i> , 2020, 5, 5.	2.9	19
221	Combined MEK and PI3K/p110 ^β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features. <i>Cancer Research</i> , 2020, 80, 843-856.	0.4	19
222	Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression. <i>Oncotarget</i> , 2016, 7, 50161-50179.	0.8	19
223	Wnt1 Is Anti-Lymphangiogenic in a Melanoma Mouse Model. <i>Journal of Investigative Dermatology</i> , 2012, 132, 2235-2244.	0.3	18
224	Targeting a Targeted Drug: An Approach Toward Hypoxia-Activatable Tyrosine Kinase Inhibitor Prodrugs. <i>ChemMedChem</i> , 2016, 11, 2410-2421.	1.6	18
225	Irinotecan Upregulates Fibroblast Growth Factor Receptor 3 Expression in Colorectal Cancer Cells, Which Mitigates Irinotecan-Induced Apoptosis. <i>Translational Oncology</i> , 2017, 10, 332-339.	1.7	18
226	Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma: Increased Cell Migration and Its Association with EGFR Expression. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4484.	1.8	18
227	Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated ROS1/NTRK-Fusion Positive Pediatric High-Grade Glioma. <i>Journal of Personalized Medicine</i> , 2020, 10, 290.	1.1	18
228	CD44 drives aggressiveness and chemoresistance of a metastatic human osteosarcoma xenograft model. <i>Oncotarget</i> , 2017, 8, 114095-114108.	0.8	18
229	Expression of the lung resistance-related protein in human and rat hepatocarcinogenesis. <i>American Journal of Physiology - Renal Physiology</i> , 2002, 283, G1117-G1124.	1.6	17
230	Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i> . <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2357-2369.	1.9	17
231	Post-digestion stabilization of osmium enables quantification by ICP-MS in cell culture and tissue. <i>Analyst</i> , 2017, 142, 2327-2332.	1.7	17
232	¹²⁴ I Radiolabeling of a Au ^{III} -NHC Complex for In Vivo Biodistribution Studies. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 17130-17136.	7.2	17
233	Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study. <i>Translational Lung Cancer Research</i> , 2021, 10, 1594-1607.	1.3	17
234	Erythropoietin Receptor Expression Is a Potential Prognostic Factor in Human Lung Adenocarcinoma. <i>PLoS ONE</i> , 2013, 8, e77459.	1.1	17

#	ARTICLE	IF	CITATIONS
235	A novel bioassay for P-glycoprotein functionality using cytochalasin D. , 1998, 31, 187-198.		16
236	Bimodal expression of Sprouty2 during the cell cycle is mediated by phase-specific Ras/MAPK and c-Cbl activities. Cellular and Molecular Life Sciences, 2010, 67, 3299-3311.	2.4	16
237	Response of experimental malignant melanoma models to the pan-Aurora kinase inhibitor VE-465. Experimental Dermatology, 2010, 19, 1040-1047.	1.4	16
238	Overexpression of Aurora-A in primary cells interferes with S-phase entry by diminishing Cyclin D1 dependent activities. Molecular Cancer, 2011, 10, 28.	7.9	16
239	Impact of terminal dimethylation on the resistance profile of \pm -N-heterocyclic thiosemicarbazones. Biochemical Pharmacology, 2012, 83, 1623-1633.	2.0	16
240	Influence of extracellular pH on the cytotoxicity, cellular accumulation, and DNA interaction of novel pH-sensitive 2-aminoalcoholatoplatinum(II) complexes. Journal of Biological Inorganic Chemistry, 2013, 18, 249-260.	1.1	16
241	Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells. BMC Cancer, 2018, 18, 542.	1.1	16
242	Lipid droplet-mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib. International Journal of Cancer, 2020, 147, 1680-1693.	2.3	16
243	Cisplatin Uptake in Macrophage Subtypes at the Single-Cell Level by LA-ICP-TOFMS Imaging. Analytical Chemistry, 2021, 93, 16456-16465.	3.2	16
244	Cytogenetic and comparative genomic hybridization findings in four cases of breast cancer after neoadjuvant chemotherapy. Cancer Genetics and Cytogenetics, 2003, 146, 161-166.	1.0	15
245	Intrathoracic solitary fibrous tumor – an international multicenter study on clinical outcome and novel circulating biomarkers. Scientific Reports, 2017, 7, 12557.	1.6	15
246	Novel Insights into Diagnosis, Biology and Treatment of Primary Diffuse Leptomeningeal Melanomatosis. Journal of Personalized Medicine, 2021, 11, 292.	1.1	15
247	Loss of phosphodiesterase 4D mediates acquired triapine resistance via Epac-Rap1-Integrin signaling. Oncotarget, 2016, 7, 84556-84574.	0.8	15
248	Effects of Multidrug Resistance-Related ATP-Binding-Cassette Transporter Proteins on the Cytoskeletal Activity of Cytochalasins. Experimental Cell Research, 1997, 237, 307-317.	1.2	14
249	Opposing Roles of JNK and p38 in Lymphangiogenesis in Melanoma. Journal of Investigative Dermatology, 2016, 136, 967-977.	0.3	14
250	Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance. British Journal of Cancer, 2017, 116, 489-500.	2.9	14
251	Ein Organoruthenium-Tumorthapeutikum mit unerwartet hoher Selektivität für Plectin. Angewandte Chemie, 2017, 129, 8379-8383.	1.6	14
252	Metal drugs become targeted. ESMO Open, 2017, 2, e000239.	2.0	14

#	ARTICLE	IF	CITATIONS
253	Targeting fibroblast growth factor receptors to combat aggressive ependymoma. <i>Acta Neuropathologica</i> , 2021, 142, 339-360.	3.9	14
254	Challenges and Chances in the Preclinical to Clinical Translation of Anticancer Metallo drugs. <i>2-Oxoglutarate-Dependent Oxygenases</i> , 2019, , 308-347.	0.8	14
255	Altered membrane rigidity via enhanced endogenous cholesterol synthesis drives cancer cell resistance to destruxins. <i>Oncotarget</i> , 2018, 9, 25661-25680.	0.8	14
256	The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation. <i>Pharmaceutics</i> , 2022, 14, 238.	2.0	14
257	Trivanillic polyphenols with anticancer cytostatic effects through the targeting of multiple kinases and intracellular Ca ²⁺ release. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 1421-1434.	1.6	13
258	Canine and human sarcomas exhibit predominant FGFR1 expression and impaired viability after inhibition of signaling. <i>Molecular Carcinogenesis</i> , 2015, 54, 841-852.	1.3	13
259	Ex-vivo analysis of quantitative 5-ALA fluorescence intensity in diffusely infiltrating gliomas using a handheld spectroscopic probe: Correlation with histopathology, proliferation and microvascular density. <i>Photodiagnosis and Photodynamic Therapy</i> , 2019, 27, 354-361.	1.3	13
260	FGF8 induces therapy resistance in neoadjuvantly radiated rectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 77-86.	1.2	13
261	Interaction of FGF9 with FGFR3 β /IIIc, a putative driver of growth and aggressive behaviour of hepatocellular carcinoma. <i>Liver International</i> , 2020, 40, 2279-2290.	1.9	13
262	Comparative analysis of prognostic histopathologic parameters in subtypes of epithelioid pleural mesothelioma. <i>Histopathology</i> , 2020, 77, 55-66.	1.6	13
263	Overexpression of Hsp27 in a human melanoma cell line: regulation of E-cadherin, MUC18/MCAM, and plasminogen activator (PA) system. <i>Cell Stress and Chaperones</i> , 2003, 8, 249.	1.2	13
264	Human tripartite motif protein 52 is required for cell context-dependent proliferation. <i>Oncotarget</i> , 2018, 9, 13565-13581.	0.8	13
265	Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines. <i>Cancer Letters</i> , 2009, 277, 218-226.	3.2	12
266	Bilberry extract, its major polyphenolic compounds, and the soy isoflavone genistein antagonize the cytostatic drug erlotinib in human epithelial cells. <i>Food and Function</i> , 2016, 7, 3628-3636.	2.1	12
267	Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma. <i>Scientific Reports</i> , 2017, 7, 16456.	1.6	12
268	Magnetic Temperature-Sensitive Solid-Lipid Particles for Targeting and Killing Tumor Cells. <i>Frontiers in Chemistry</i> , 2020, 8, 205.	1.8	12
269	The FAM3C locus that encodes interleukin-like EMT inducer (ILEI) is frequently co-amplified in MET-amplified cancers and contributes to invasiveness. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 69.	3.5	12
270	The role of reactive oxygen species in tumor cells apoptosis induced by landomycin A. <i>Ukrainian Biochemical Journal</i> , 2015, 87, 72-82.	0.1	12

#	ARTICLE	IF	CITATIONS
271	A small upstream open reading frame causes inhibition of human major vault protein expression from a ubiquitous mRNA splice variant. <i>FEBS Letters</i> , 2001, 494, 99-104.	1.3	11
272	MAP kinase activity supported by BRAF V600E mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases. <i>Archives of Dermatological Research</i> , 2014, 306, 873-884.	1.1	11
273	Nanoformulations of anticancer thiosemicarbazones to reduce methemoglobin formation and improve anticancer activity. <i>RSC Advances</i> , 2016, 6, 55848-55859.	1.7	11
274	Development and biological investigations of hypoxia-sensitive prodrugs of the tyrosine kinase inhibitor crizotinib. <i>Bioorganic Chemistry</i> , 2020, 99, 103778.	2.0	11
275	Results of the extended analysis for cancer treatment (EXACT) trial: a prospective translational study evaluating individualized treatment regimens in oncology. <i>Oncotarget</i> , 2019, 10, 942-952.	0.8	11
276	Molecular and Pharmacological Bladder Cancer Therapy Screening: Discovery of Clofarabine as a Highly Active Compound. <i>European Urology</i> , 2022, 82, 261-270.	0.9	11
277	Effects of the anthelmintic drug PF1022A on mammalian tissue and cells. <i>Biochemical Pharmacology</i> , 2009, 77, 1437-1444.	2.0	10
278	2-Deprenyl-Rheediaxanthone B Isolated from <i>Metaxya rostrata</i> Induces Active Cell Death in Colorectal Tumor Cells. <i>PLoS ONE</i> , 2013, 8, e65745.	1.1	10
279	Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations. <i>Pathology and Oncology Research</i> , 2015, 21, 957-968.	0.9	10
280	Computed determination of the in vitro optimal chemocombinations of sphaeropsidin A with chemotherapeutic agents to combat melanomas. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 971-983.	1.1	10
281	Expression of FGFR1 ⁴ in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity. <i>Cells</i> , 2019, 8, 1091.	1.8	10
282	Subcellular Duplex DNA and G ₄ Quadruplex Interaction Profiling of a Hexagonal Pt II Metallacycle. <i>Angewandte Chemie</i> , 2019, 131, 8091-8096.	1.6	10
283	The study of reduced versus oxidized glutathione in cancer cell models employing isotopically labelled standards. <i>Analytical Methods</i> , 2014, 6, 3086-3094.	1.3	9
284	Synthesis, Characterization and <i>in vitro</i> Studies of a Cathepsin B-Cleavable Prodrug of the VEGFR Inhibitor Sunitinib. <i>Chemistry and Biodiversity</i> , 2019, 16, e1800520.	1.0	9
285	Landomycins as glutathione-depleting agents and natural fluorescent probes for cellular Michael adduct-dependent quinone metabolism. <i>Communications Chemistry</i> , 2021, 4, .	2.0	9
286	EGCG-mediated cyto- and genotoxicity in HaCat keratinocytes is impaired by cell-mediated clearance of auto-oxidation-derived H ₂ O ₂ : An algorithm for experimental setting correction. <i>Toxicology Letters</i> , 2011, 205, 173-182.	0.4	8
287	Tumorspezifische, Hypoxie-basierte Aktivierung von EGFR-Inhibitoren. <i>Angewandte Chemie</i> , 2014, 126, 13144-13149.	1.6	8
288	Lysosomal Sequestration Impairs the Activity of the Preclinical FGFR Inhibitor PD173074. <i>Cells</i> , 2018, 7, 259.	1.8	8

#	ARTICLE	IF	CITATIONS
289	The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivo A Comparison of O,O -S,O - and N , N -Chelate Effects. <i>Chemistry - A European Journal</i> , 2020, 26, 2211-2221.	1.7	8
290	p53 Loss Mediates Hypersensitivity to ETS Transcription Factor Inhibition Based on PARylation-Mediated Cell Death Induction. <i>Cancers</i> , 2020, 12, 3205.	1.7	8
291	Chronic arsenic trioxide exposure leads to enhanced aggressiveness via Met oncogene addiction in cancer cells. <i>Oncotarget</i> , 2016, 7, 27379-27393.	0.8	8
292	Fibroblast growth factor receptor 4 promotes glioblastoma progression: a central role of integrin-mediated cell invasiveness. <i>Acta Neuropathologica Communications</i> , 2022, 10, 65.	2.4	8
293	Bis-hydroxyquinoline and bis-hydroxyquinaldine <i>N</i> -substituted amines: A single methyl group structural difference between the two heterocycles, which modulates the antiproliferative effects. <i>Journal of Heterocyclic Chemistry</i> , 2010, 47, 719-723.	1.4	7
294	Spheroid glioblastoma culture conditions as antigen source for dendritic cell-based immunotherapy: spheroid proteins are survival-relevant targets but can impair immunogenic interferon γ production. <i>Cytotherapy</i> , 2019, 21, 643-658.	0.3	7
295	Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI. <i>ESMO Open</i> , 2019, 4, e000538.	2.0	7
296	Stable Protein Expression in Mammalian Cells Using Baculoviruses. <i>Methods in Molecular Biology</i> , 2012, 801, 75-92.	0.4	6
297	Dynamics of CRISPR/Cas9-mediated genomic editing of the AXL locus in hepatocellular carcinoma cells. <i>Oncology Letters</i> , 2018, 15, 2441-2450.	0.8	6
298	Development of a cobalt(<i>III</i>)-based ponatinib prodrug system. <i>Inorganic Chemistry Frontiers</i> , 2021, 8, 2468-2485.	3.0	6
299	[^{11}C]Erlotinib PET cannot detect acquired erlotinib resistance in NSCLC tumor xenografts in mice. <i>Nuclear Medicine and Biology</i> , 2017, 52, 7-15.	0.3	6
300	Chemoresistance of Human Malignant Melanoma: Cellular and Molecular Aspects. <i>Oncology Research and Treatment</i> , 1998, 21, 105-110.	0.8	5
301	Water-soluble Cationic Derivatives of Indirubin, the Active Anticancer Component from <i>Indigo naturalis</i> . <i>Chemistry and Biodiversity</i> , 2012, 9, 2175-2185.	1.0	5
302	Design, synthesis, nuclear localization, and biological activity of a fluorescent duocarmycin analog, HxTfA. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 1342-1347.	1.0	5
303	^{124}I Radiolabeling of a Au III -NHC Complex for In Vivo Biodistribution Studies. <i>Angewandte Chemie</i> , 2020, 132, 17278-17284.	1.6	5
304	Thermodynamic Genome-Scale Metabolic Modeling of Metallodrug Resistance in Colorectal Cancer. <i>Cancers</i> , 2021, 13, 4130.	1.7	5
305	Detection and quantification of transcripts for the catalytic subunit TERT and the RNA component of telomerase in rat tissue. <i>Analytical Biochemistry</i> , 2003, 317, 120-123.	1.1	4
306	A bicistronic baculovirus vector for transient and stable protein expression in mammalian cells. <i>Analytical Biochemistry</i> , 2008, 380, 146-148.	1.1	4

#	ARTICLE	IF	CITATIONS
307	Non-viral gene delivery of the oncotoxic protein NS1 for treatment of hepatocellular carcinoma. <i>Journal of Controlled Release</i> , 2021, 334, 138-152.	4.8	3
308	Chromosomal dynamics of cell cycle regulator gene p21 during transcriptional activation. <i>Journal of Structural Biology</i> , 2011, 173, 382-390.	1.3	2
309	Multicellular contractility contributes to the emergence of mesothelioma nodules. <i>Scientific Reports</i> , 2020, 10, 20114.	1.6	2
310	Die Wechselwirkung mit ribosomalen Proteinen begleitet die Stressinduktion des Wirkstoffkandidaten BOLD-100/KP1339 im endoplasmatischen Retikulum. <i>Angewandte Chemie</i> , 2021, 133, 5121-5126.	1.6	2
311	Feasibility of personalized treatment concepts in gastrointestinal malignancies: Sub-group results of prospective clinical phase II trial EXACT. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2018, 30, 508-515.	0.7	2
312	Molecular oncology in lung cancer – between biomarkers and clinical application. Relevance of the Ras-Raf-MEK-ERK pathway. <i>Memo - Magazine of European Medical Oncology</i> , 2011, 4, 242-247.	0.3	1
313	Abstract 1067: Targeting the fibroblast growth factor receptor axis in malignant pleural mesothelioma. , 2012, , .		1
314	CSIG-04. UNCOUPLING OF ETS1 FROM MAPK PATHWAY SIGNALS AS RESISTANCE MECHANISM TOWARDS BRAF INHIBITORS IN BRAF-MUTATED CHILDHOOD GLIOMA. <i>Neuro-Oncology</i> , 2021, 23, vi33-vi34.	0.6	1
315	CSIG-30. TARGETING TELOMERASE VIA MEK INHIBITION IN AGGRESSIVE TERT PROMOTER MUTATED BRAIN TUMORS. <i>Neuro-Oncology</i> , 2021, 23, vi39-vi40.	0.6	1
316	Fibroblast growth factor receptors (FGFR) as possible therapeutic targets in human non-small cell lung cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2010, 3, 23-26.	0.3	0
317	A critical update on prognostic and predictive biomarkers in malignant pleural mesothelioma. <i>Memo - Magazine of European Medical Oncology</i> , 2015, 8, 52-56.	0.3	0
318	32nd International Austrian Winter Symposium. <i>EJNMMI Research</i> , 2016, 6, 32.	1.1	0
319	Innentitelbild: Ein Organoruthenium-umtherapeutikum mit unerwartet hoher Selektivität für Plectin (<i>Angew. Chem.</i> 28/2017). <i>Angewandte Chemie</i> , 2017, 129, 8415-8415.	1.6	0
320	P04.51 TERT promoter mutation-driven TERT activation is mediated by ETS1 in BRAF V600E mutated glioma. <i>Neuro-Oncology</i> , 2018, 20, iii290-iii291.	0.6	0
321	Deciphering the chemical instability of sphaeropsidin A under physiological conditions – degradation studies and structural elucidation of the major metabolite. <i>Organic and Biomolecular Chemistry</i> , 2020, 18, 8147-8160.	1.5	0
322	Innentitelbild: Die Wechselwirkung mit ribosomalen Proteinen begleitet die Stressinduktion des Wirkstoffkandidaten BOLD-100/KP1339 im endoplasmatischen Retikulum (<i>Angew. Chem.</i> 10/2021). <i>Angewandte Chemie</i> , 2021, 133, 5006-5006.	1.6	0
323	Abstract B37: Prenylation inhibition induces cell death in NRAS mutant melanoma cells. , 2014, , .		0
324	Mitochondria do not play a major role in landomycin E-induced ROS burst and circumvention of multiple drug resistance in HL-60 leukemia cells. <i>Biopolymers and Cell</i> , 2016, 32, 190-202.	0.1	0

#	ARTICLE	IF	CITATIONS
325	EPEN-21. IMPAIRED NEURONAL-GLIAL FATE SPECIFICATION IN PEDIATRIC EPENDYMOMA REVEALED BY SINGLE-CELL RNA-SEQ. <i>Neuro-Oncology</i> , 2020, 22, iii311-iii312.	0.6	0
326	CBIO-22. PARP INHIBITION SYNERGIZES WITH DNA DAMAGING DRUGS IN PEDIATRIC CNS TUMORS. <i>Neuro-Oncology</i> , 2021, 23, vi31-vi31.	0.6	0
327	EPKO-35. SINGLE-CELL RNA-SEQ OF PEDIATRIC EPENDYMOMA REVEALS PROGNOSTIC IMPACT OF IMPAIRED NEURONAL-GLIAL FATE SPECIFICATION. <i>Neuro-Oncology</i> , 2020, 22, ii76-ii77.	0.6	0
328	HGG-50. Specific sensitivity of pediatric high-grade glioma with ATRX inactivation to PARP inhibitor combinations. <i>Neuro-Oncology</i> , 2022, 24, i73-i73.	0.6	0
329	ETMR-12. Novel cell models of CNS tumors with BCOR fusion or internal tandem duplication suggest FGFR and PDGFR as promising therapy targets. <i>Neuro-Oncology</i> , 2022, 24, i52-i52.	0.6	0
330	ETMR-11. Transcriptional changes upon knockdown of altered <i>BCOR/BCORL1</i> transcripts in preclinical models of CNS embryonal tumors with BCOR-related alterations. <i>Neuro-Oncology</i> , 2022, 24, i51-i52.	0.6	0
331	EPEN-23. Interaction of epigenetic regulation and telomerase re-activation in high-risk ependymoma. <i>Neuro-Oncology</i> , 2022, 24, i43-i43.	0.6	0
332	MODL-14 Inhibition of cell cycle mechanisms to combat high-risk medulloblastoma. <i>Neuro-Oncology</i> , 2022, 24, i171-i171.	0.6	0
333	MEDB-82. Exploring cell-cell communication networks in medulloblastoma using single-cell genomics. <i>Neuro-Oncology</i> , 2022, 24, i125-i126.	0.6	0